ArticleBMC biotechnology2025
Biosynthesis of silver nanoparticles using Phoma herbarum and evaluation of their fungicidal effects against onion basal root rot disease.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Silver Nanoparticles in Antibacterial Research: Mechanisms, Applications, and Emerging Perspectives.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate the effectiveness of a new alternative biofungicidal product in controlling the fungal disease agent, Fusarium oxysporum f. sp. cepae, which causes considerable losses during onion storage. In the first stage of this study, silver nanoparticles derived from the microorganism (Phoma herbarum) were biosynthesized using the green synthesis method in nanotechnology. Characterisation tests of the nano product, which was synthesized through the biosynthesis process, confirmed that it is a silver-based nano product with size dimensions ranging from 4 to 40 nm. In the second phase of the study, the fungicidal efficacy of the synthesized silver nanoparticle product, at concentrations ranging from 2.5 to 500 ppm, was investigated against pathogenic fungi. Its effectiveness was evaluated under both in vitro and in vivo conditions. In the in vitro study conducted in petri dishes, the highest mycelial growth, 87.66 ± 0.57 mm, was observed in the control group. Following the application of 2.5 and 5 ppm silver nanoparticles, the mycelium diameter measured 86.66 ± 1.15 mm. However, as the concentration of silver nanoparticles increased, a significant reduction in mycelial growth was observed. At 200 ppm, the mycelial diameter decreased to 10.66 ± 1.15 mm; at 500 ppm, no mycelial growth was observed. In the in vivo study conducted on onion bulbs, the fungicidal activity of silver nanoparticles was evaluated by measuring the disease inhibition rates after the application of silver nanoparticles on the bulbs. When disease inhibition rates are compared in onion bulbs, the dose-dependent rot diameters are as follows: positive control(50.20 ± 0.20 mm); 10 ppm (34.60 ± 0.50 mm); 25 ppm (27.60 ± 0.30 mm); 50 ppm (19.00 ± 0.38); 100 ppm (12.00 ± 0.40); 200 ppm (6.80 ± 0.31 mm) and 500 ppm (1.20 ± 0.17 mm). In addition to these results, different concentrations of silver nanoparticles demonstrated a dose-dependent reduction in disease incidence, ranging from 28.89% to 94.42%. When evaluated collectively, the results indicated that silver nanoparticles synthesized through the green synthesis method exhibited varying degrees of fungicidal activity under both in vitro and in vivo conditions, with effectiveness dependent on the concentration applied. Consequently, the synthesized silver nanoparticles product has demonstrated considerable potential as an alternative solution for effectively managing Fusarium oxysporum f. sp. cepae a significant threat to stored onion bulbs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.